OABI (OmniAb) Market Cap : $305.95 Mil (As of Mar. 23, 2025)

View and export this data going back to 2022. Start your Free Trial

What is OmniAb Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). OmniAb's share price for the quarter that ended in Dec. 2024 was $3.54. OmniAb's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 121.60 Mil. Therefore, OmniAb's market cap for the quarter that ended in Dec. 2024 was $430.46 Mil.

OmniAb's quarterly market cap increased from Jun. 2024 ($443.09 Mil) to Sep. 2024 ($508.54 Mil) but then declined from Sep. 2024 ($508.54 Mil) to Dec. 2024 ($430.46 Mil).

OmniAb's annual market cap increased from Dec. 2022 ($414.78 Mil) to Dec. 2023 ($721.02 Mil) but then declined from Dec. 2023 ($721.02 Mil) to Dec. 2024 ($430.46 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. OmniAb's Enterprise Value for Today is $269.68 Mil.

OmniAb Market Cap Historical Data

The historical data trend for OmniAb's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OmniAb Market Cap Chart

OmniAb Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Market Cap

Get a 7-Day Free Trial

414.78

721.02

430.46

OmniAb Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Market Cap	Get a 7-Day Free Trial												721.02	636.25	443.09	508.54	430.46

Competitive Comparison of OmniAb's Market Cap

For the Biotechnology subindustry, OmniAb's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OmniAb's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's Market Cap distribution charts can be found below:

* The bar in red indicates where OmniAb's Market Cap falls into.

OmniAb Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

OmniAb's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as

Market Cap (A: Dec. 2024 )	=	Share Price (A: Dec. 2024 )	*	Shares Outstanding (EOP) (A: Dec. 2024 )
	=	$3.54	*	121.599
	=	$430.46

OmniAb's Market Cap for the quarter that ended in Dec. 2024 is calculated as

Market Cap (Q: Dec. 2024 )	=	Share Price (Q: Dec. 2024 )	*	Shares Outstanding (EOP) (Q: Dec. 2024 )
	=	$3.54	*	121.599
	=	$430.46

OmniAb (NAS:OABI) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

OmniAb Market Cap Related Terms

Thank you for viewing the detailed overview of OmniAb's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

OmniAb Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OmniAb Inc (NAS:OABI) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608

Website

https://www.omniab.com

OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Executives

John L Higgins	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Kurt A Gustafson	officer: EVP, Finance and CFO	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Matthew W Foehr	director, officer: President & CEO	11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Charles S Berkman	officer: See Remarks	11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Steven Love	director	C/O OMNIAB, INC., 5980 HORTON STREET, SUITE 600, EMERYVILLE CA 94608
Carolyn R Bertozzi	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Avista Capital Managing Member V, Llc	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V Gp, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners (offshore) V, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jennifer R. Cochran	director	C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Thompson Dean	director, 10 percent owner	65 EAST 55TH STREET, 18TH FLOOR, C/O AVISTA CAPITAL PARTNERS, NEW YORK NY 10022
Avista Acquisition Lp Ii	director, 10 percent owner	C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Acquisition Gp Llc Ii	director, 10 percent owner	C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
David F Burgstahler	director, 10 percent owner	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866